RxDoctor Payments Data

Xiaohuan Li, MD

Internal Medicine · Raleigh, NCNPI 1225425333

Payments from drug & device makers

$1,684in general payments, 2019–2025

Across 63 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$524
  • AstraZeneca$384
  • AbbVie$282
  • Lilly USA, LLC$130
  • Johnson & Johnson$64
  • Merck$59
  • plus $241 from 8 others

What the payments were for

  • Food & beverage$1,684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,684 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,096
Medicare patients
93
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide22$33,402
FarxigaDapagliflozin Propanediol31$27,233
JardianceEmpagliflozin18$17,932
Atorvastatin Calcium215$2,116
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,736
Rosuvastatin Calcium101$1,353
Albuterol Sulfate HfaAlbuterol Sulfate54$1,257
Amlodipine Besylate164$1,139
Metoprolol Succinate88$1,091
Valsartan27$922
Losartan Potassium91$918
Omeprazole39$590
Gabapentin34$559
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide15$533
Levothyroxine Sodium62$514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$524$33,40222 claims
AstraZenecaFarxiga$384$27,23331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →